| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef2e9f5ce8630d9b282043b8d060caff |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-16 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C335-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C335-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C335-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C335-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C335-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C335-14 |
| filingDate |
2002-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96c7a16f619968af7c285c6eadc4e01e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c05636a0a90c6f6d04fc51029072241
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e50d1ea0e9c8b06e9ff5228a8ed9246a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22cbce8c477f3d5802189fcb11ba68d1 |
| publicationDate |
2004-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1381593-A2 |
| titleOfInvention |
(2-hydroxy)ethyl-thioureas useful as modulators of alpha2b adrenergic receptors |
| abstract |
Compounds of formula (i) and of formula (ii), wherein the symbols have the meaning disclosed in the claims, specifically or selectively modulate α2A adrenergic receptors and as such are useful for alleviating chronic pain and allodynia and have no or only minimal cardiovascular and/or sedatory activity. The invention also relates to a method of activating α2B or α2C adrenergic receptors in a mammal by administering a compound that has α2Bor α2C adrenergic receptor activity and has no significant α2A agonist activity. |
| priorityDate |
2001-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |